This years meeting focus is very much inline with Pharmidex areas of operation and interest. We look forward to seeing you there on the 17th of March 2016

Modern drug discovery undergoes continual change in our efforts to more effectively design new life changing therapeutics for patients. One area that has seen a massive increase in focus in recent years has been the need for more translational approaches to many if not all therapeutic areas.

This has stemmed from the increasing appreciation that many of the cellular and animal models, traditionally used for the assessment of efficacy, currently have limited predictive validity to the human diseases we are trying to treat. Additionally, target selection based solely on preclinical validation may be leading to flawed biological hypothesise for putative therapeutics. Together these factors have contributed to the poor clinical success rate in many diseases. As a result there has been an increased focus on identify targets based on a strong understanding of human genetics and disease biology. Additionally drug discovery teams are increasingly co- developing translational approaches to demonstrate target engagement and proof of pharmacology whilst identifying biomarkers to stratify patient populations in which to optimally test proof of concept.



This meeting brings together experts from a variety of imaging and preclinical model backgrounds across a range of diseases (dementia, pain and oncology) to present and discuss their experiences in the various aspects of translational science. This promises to be an exciting and interesting meeting with in depth discussion into how the drug discovery community can better target disease processes, more optimally test novel therapeutics in appropriate populations and ultimately enhance clinical success in producing efficacious therapeutics for patients.

Please see the link for further details: http://www.smr.org.uk/SMR/Meetings/20160317/Default.asp